| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.3 | 2e-17 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.3 | 1e-16 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | 0.25 | 3e-14 |
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | 0.23 | 4e-14 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | 0.25 | 5e-14 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.37 | 1e-13 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | 0.24 | 2e-13 |
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | 0.23 | 7e-13 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | 0.23 | 3e-11 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.23 | 6e-11 |